Megha Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Megha Shah has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Brent McMonagle
Menzies Health Institute Queensland, Griffith University, Southport, Qld 4222, Australia
1 shared publication - Dinesh Palipana
Australian Centre for Precision Health and Technology; Griffith University, Gold Coast campus; Southport Australia
1 shared publication - James A. St. John
Clem Jones Centre for Neurobiology and Stem Cell Research, Institute for Biomedicine and Glycomics, Griffith University, Parklands Drive, Gold Coast, QLD 4222, Australia
1 shared publication - Jenny A. K. Ekberg
Menzies Health Institute Queensland and School of Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia
1 shared publication - Marie-Laure Vial
Menzies Health Institute Queensland, Griffith University, Southport, Qld 4222, Australia
1 shared publication - Mariyam Murtaza
Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia
1 shared publication
Latest Publications
- Open Access
- 6 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3153
Designing a Clinical Trial with Olfactory Ensheathing Cell Transplantation-Based Therapy for Spinal Cord Injury: A Position Paper
Spinal cord injury (SCI) represents an urgent unmet need for clinical reparative therapy due to its largely irreversible and devastating effects on patients, and the tremendous socioeconomic burden to the community. While different approaches are being explored, therapy to restore the lost function remains unavailable. Olfactory ensheathing cell (OEC) transplantation is a promising approach in terms of feasibility, safety, and limited efficacy; however, high variability in reported clinical outcomes prevent its translation despite several clinical trials. The aims of this position paper are to present an in-depth analysis of previous OEC transplantation-based clinical trials, identify existing challenges and gaps, and finally propose strategies to improve standardization of OEC therapies. We have reviewed the study design and protocols of clinical trials using OEC transplantation for SCI repair to investigate how and why the outcomes show variability. With this knowledge and our experience as a team of biologists and clinicians with active experience in the field of OEC research, we provide recommendations regarding cell source, cell purity and characterisation, transplantation dosage and format, and rehabilitation. Ultimately, this position paper is intended to serve as a roadmap to design an effective clinical trial with OEC transplantation-based therapy for SCI repair.
- 6 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3153
Open AccessDesigning a Clinical Trial with Olfactory Ensheathing Cell Transplantation-Based Therapy for Spinal Cord Injury: A Position Paper
Spinal cord injury (SCI) represents an urgent unmet need for clinical reparative therapy due to its largely irreversible and devastating effects on patients, and the tremendous socioeconomic burden to the community. While different approaches are being explored, therapy to restore the lost function remains unavailable. Olfactory ensheathing cell (OEC) transplantation is a promising approach in terms of feasibility, safety, and limited efficacy; however, high variability in reported clinical outcomes prevent its translation despite several clinical trials. The aims of this position paper are to present an in-depth analysis of previous OEC transplantation-based clinical trials, identify existing challenges and gaps, and finally propose strategies to improve standardization of OEC therapies. We have reviewed the study design and protocols of clinical trials using OEC transplantation for SCI repair to investigate how and why the outcomes show variability. With this knowledge and our experience as a team of biologists and clinicians with active experience in the field of OEC research, we provide recommendations regarding cell source, cell purity and characterisation, transplantation dosage and format, and rehabilitation. Ultimately, this position paper is intended to serve as a roadmap to design an effective clinical trial with OEC transplantation-based therapy for SCI repair.